Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

Decision Science Asset Diversification Versus Concentration

White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

Achieving Sales Operations Excellence With Intelligent Roster Management

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

The Reasons for and Solutions to Chronic Drug Shortages in the United States

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

Pricing and Market Effects of Biosimilar Entry in the US

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

The Importance of Governance in Your Incentive Compensation Program

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

Designing Incentive Compensation Plans for Specialty Products

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

State Of Commercial Excellence 2017 - Part 1

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

White paper

Better Reporting With The IPad

Good reporting is an essential tool for managing your business. This reporting needs to be focused and actionable – focused in that it addresses the key business questions you fa ...

White paper

Payer Influence On Product Performance In Pharmaceutical Industry

Payers vary in their ability to assert formulary compliance. We will explore how tools and analytics can enable a pharmaceutical manufacturer to assess factors impacting formulary ...

White paper

Account Based Models In An Institutional Setting

The stakeholders and factors that drive the ultimate prescribing of a medication have shifted considerably since the turn of the century. ...

The Importance of Governance in Your Incentive Compensation Program

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

Designing Incentive Compensation Plans for Specialty Products

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

State Of Commercial Excellence 2017 - Part 1

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Do You Know The Answers To Your Important Territory Alignment Questions

White paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

White paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

Commercial Operations Capabilities Excellence And Business Performance

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

White paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

State Of Commercial Excellence 2017 - Part 1

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Make US Pharma Great Again!? - Part 1

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Patient Claims Versus EHR Data – How To Choose Between The Two?

White paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

White paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

Let us help your business today.
Contact us now to start your journey.